Emerging Strategies for the Treatment of Tumor Stem Cells in Central Nervous System Malignancies

  • Imad Saeed Khan
  • Moneeb EhteshamEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 853)


High-grade central nervous system (CNS) tumors are notorious for high rates of recurrence and poor outcomes. A small cohort of tumor cells, dubbed tumor stem cells (TSC), are now being recognized as an important subset of the tumor that is resistant to chemotherapy and radiotherapy and account for the high recurrence rates. Recent research is developing modalities to target TSCs specifically in a bid to improve the response of the tumor as a whole. The methods being employed to target TSCs include targeting TSC-specific pathways or receptors, TSC-sensitizing agents to chemotherapy and radiotherapy, immunotherapy, TSC-differentiating agents, and viral therapy. This chapter provides an overview of strategies that are expected to help develop new and more effective treatments for CNS tumors.


Glioma stem cells Tumor stem cells Cancer stem cells Chemotherapy sensitization Radiotherapy sensitization Immunotherapy Differentiation agents Virotherapy Gene therapy 


  1. 1.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.PubMedGoogle Scholar
  2. 2.
    Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66(19):9339–44.PubMedGoogle Scholar
  3. 3.
    Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012;14(2):132–44.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Kelly JJP, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells (Dayton Ohio). 2009;27(8):1722–33.Google Scholar
  5. 5.
    Zhang J, Stevens MFG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5(1):102–14.PubMedGoogle Scholar
  6. 6.
    Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.PubMedGoogle Scholar
  7. 7.
    Cho D-Y, Lin S-Z, Yang W-K, Lee H-C, Hsu D-M, Lin H-L, et al. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant. 2013;22(4):731–9.PubMedGoogle Scholar
  8. 8.
    Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Fu J, Liu Z, Liu X, Chen F, Shi H, Pangjesse C, et al. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Chin Med J (Engl). 2009;122(11):1255–9.Google Scholar
  10. 10.
    Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, et al. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest. 2009;27(9):901–8.PubMedGoogle Scholar
  11. 11.
    Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008;68(14):5706–15.PubMedGoogle Scholar
  12. 12.
    Oka N, Soeda A, Noda S, Iwama T. Brain tumor stem cells from an adenoid glioblastoma multiforme. Neurol Med Chir (Tokyo). 2009;49(4):146–50. discussion 150–1.Google Scholar
  13. 13.
    Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2008;10(5):262–7.Google Scholar
  14. 14.
    Sakariassen PØ, Immervoll H, Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia. 2007;9(11):882–92.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Schmalz PGR, Shen MJ, Park JK. Treatment resistance mechanisms of malignant glioma tumor stem cells. Cancers. 2011;3(1):621–35.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756–60.PubMedGoogle Scholar
  17. 17.
    Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res. 2009;7(3):383–92.PubMedGoogle Scholar
  18. 18.
    Nicolis SK. Cancer stem cells and “stemness” genes in neuro-oncology. Neurobiol Dis. 2007;25(2):217–29.PubMedGoogle Scholar
  19. 19.
    Luther N, Cheung N-K, Souliopoulos EP, Karampelas I, Karempelas I, Bassiri D, et al. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol Cancer Ther. 2010;9(4):1039–46.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Cho D-Y, Lin S-Z, Yang W-K, Hsu D-M, Lee H-C, Lee W-Y, et al. Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas. Cell Transplant. 2009;18(9):977–83.PubMedGoogle Scholar
  21. 21.
    Piccirillo SGM, Vescovi AL. Brain tumour stem cells: possibilities of new therapeutic strategies. Expert Opin Biol Ther. 2007;7(8):1129–35.PubMedGoogle Scholar
  22. 22.
    Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1(5):466–76.PubMedGoogle Scholar
  23. 23.
    Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG. Notch3 signaling initiates choroid plexus tumor formation. Oncogene. 2006;25(3):487–91.PubMedGoogle Scholar
  24. 24.
    Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004;104(12):3697–704.PubMedGoogle Scholar
  25. 25.
    Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells (Dayton Ohio). 2010;28(6):1019–29.Google Scholar
  26. 26.
    Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3(6):565–76.PubMedGoogle Scholar
  27. 27.
    Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003;22(42):6598–608.PubMedGoogle Scholar
  28. 28.
    Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14(5):779–86.PubMedGoogle Scholar
  29. 29.
    Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004;167(2):215–21.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353–63.PubMedGoogle Scholar
  31. 31.
    Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 2011;71(18):6061–72.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011–21.PubMedGoogle Scholar
  33. 33.
    Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (Dayton Ohio). 2010;28(1):5–16.Google Scholar
  34. 34.
    Dahmane N, Ruiz i Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Dev Camb Engl. 1999;126(14):3089–100.Google Scholar
  35. 35.
    Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron. 1999;22(1):103–14.PubMedGoogle Scholar
  36. 36.
    Lee A, Kessler JD, Read T-A, Kaiser C, Corbeil D, Huttner WB, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci. 2005;8(6):723–9.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, et al. Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion. Neoplasia. 2008;10(12):1343–9. 5p following 1349.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Wang X, Venugopal C, Manoranjan B, McFarlane N, O’Farrell E, Nolte S, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene. 2012; 31(2):187–99.PubMedGoogle Scholar
  39. 39.
    Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O’Brien SJ, et al. Identification of an amplified, highly expressed gene in a human glioma. Science. 1987;236(4797):70–3.PubMedGoogle Scholar
  40. 40.
    Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (Dayton Ohio). 2007;25(10):2524–33.Google Scholar
  41. 41.
    Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17(2):165–72.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFκB dependent manner. Cancer Lett. 2013;336(2):347–58.PubMedGoogle Scholar
  43. 43.
    Barami K. Relationship of neural stem cells with their vascular niche: implications in the malignant progression of gliomas. J Clin Neurosci. 2008;15(11):1193–7.PubMedGoogle Scholar
  44. 44.
    Yan G-N, Lv Y-F, Yang L, Yao X-H, Cui Y-H, Guo D-Y. Glioma stem cells enhance endothelial cell migration and proliferation via the Hedgehog pathway. Oncol Lett. 2013;6(5):1524–30.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Meiss F, Zeiser R. Vismodegib. Recent Results Cancer Res Fortschritte Krebsforsch Prog Dans Rech Sur Cancer. 2014;201:405–17.Google Scholar
  46. 46.
    Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173–8.PubMedGoogle Scholar
  47. 47.
    Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–8.PubMedGoogle Scholar
  48. 48.
    Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.PubMedGoogle Scholar
  49. 49.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.PubMedCentralPubMedGoogle Scholar
  50. 50.
    Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–8.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.Google Scholar
  52. 52.
    Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Inda M-M, Bonavia R, Mukasa A, Narita Y, Sah DWY, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24(16):1731–45.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Jin X, Yin J, Kim S-H, Sohn Y-W, Beck S, Lim YC, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22):7125–34.PubMedGoogle Scholar
  55. 55.
    Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(8):3018–23.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK, et al. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 2014;33(19):2504–12.PubMedGoogle Scholar
  57. 57.
    Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010;12(1):95–103.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS Acta Pathol Microbiol Immunol Scand. 2010;118(8):585–94.Google Scholar
  59. 59.
    Hegi ME, Diserens A-C, Bady P, Kamoshima Y, Kouwenhoven MCM, Delorenzi M, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib—a phase II trial. Mol Cancer Ther. 2011;10(6):1102–12.PubMedGoogle Scholar
  60. 60.
    Lindvall C, Bu W, Williams BO, Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 2007;3(2):157–68.PubMedGoogle Scholar
  61. 61.
    Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129(4):199–221.PubMedGoogle Scholar
  62. 62.
    Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17(1):45–51.PubMedGoogle Scholar
  63. 63.
    Augustin I, Goidts V, Bongers A, Kerr G, Vollert G, Radlwimmer B, et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med. 2012;4(1):38–51.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt-signaling and a fingerprint associated with clinical outcome. Exp Cell Res. 2013;319(14):2230–43.PubMedGoogle Scholar
  65. 65.
    Kim KH, Seol HJ, Kim EH, Rheey J, Jin HJ, Lee Y, et al. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol. 2013;15(2):161–71.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Rogers HA, Sousa S, Salto C, Arenas E, Coyle B, Grundy RG. WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer. 2012;107(7):1144–52.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Mascaro Cordeiro B, Dias Oliveira I, de Seixas Alves MT, Saba-Silva N, Capellano AM, Cavalheiro S, et al. SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties. Childs Nerv Syst. 2014;30(7):1165–72.Google Scholar
  68. 68.
    Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4):387–90.PubMedGoogle Scholar
  69. 69.
    Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 2010;16(1):154–63.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34.PubMedGoogle Scholar
  71. 71.
    Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia. 2011;13(7):620–32.PubMedCentralPubMedGoogle Scholar
  72. 72.
    Chen L, Zhang R, Li P, Liu Y, Qin K, Fa Z-Q, et al. P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci Lett. 2013;534:327–32.PubMedGoogle Scholar
  73. 73.
    Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle Georget Tex. 2010;9(6):1031–6.Google Scholar
  74. 74.
    Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69(19):7569–76.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001;61(15):5843–9.PubMedGoogle Scholar
  76. 76.
    Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003;23(22):8306–15.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003;63(9):2139–44.PubMedGoogle Scholar
  78. 78.
    Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg. 2003;98(3):591–8.PubMedGoogle Scholar
  79. 79.
    Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 1992;51(4):613–9.PubMedGoogle Scholar
  80. 80.
    Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg. 2010;112(1):33–42.PubMedGoogle Scholar
  81. 81.
    Sauvageot CM-E, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 2009;11(2):109–21.PubMedCentralPubMedGoogle Scholar
  82. 82.
    Tentori L, Leonetti C, Scarsella M, D’Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res. 2003;9(14):5370–9.PubMedGoogle Scholar
  83. 83.
    Tentori L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D, et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol. 2005;26(2):415–22.PubMedGoogle Scholar
  84. 84.
    Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, et al. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer Oxf Engl 1990. 2005;41(18):2948–57.Google Scholar
  85. 85.
    Warrier S, Balu SK, Kumar AP, Millward M, Dharmarajan A. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res. 2014;21(2):93–102.Google Scholar
  86. 86.
    Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells’ VEGF production and angiogenesis. J Neurosurg. 2013;119(6):1415–23.PubMedGoogle Scholar
  87. 87.
    Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010;70(6):2455–64.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Wachsberger PR, Lawrence RY, Liu Y, Xia X, Andersen B, Dicker AP. Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. J Neurooncol. 2011;105(2):181–90.PubMedGoogle Scholar
  89. 89.
    Kang M-K, Kang S-K. Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem Biophys Res Commun. 2008;373(4):539–44.PubMedGoogle Scholar
  90. 90.
    Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67(8):3560–4.PubMedGoogle Scholar
  91. 91.
    Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71(23):7155–67.PubMedGoogle Scholar
  92. 92.
    Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res. 2012;72(16):4119–29.PubMedCentralPubMedGoogle Scholar
  93. 93.
    Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, et al. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer. 2008;123(1):209–16.PubMedGoogle Scholar
  94. 94.
    Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int J Radiat Oncol Biol Phys. 2012;83(1):e43–52.PubMedGoogle Scholar
  95. 95.
    Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (’Iressa’). Cancer Lett. 2003;202(1):43–51.PubMedGoogle Scholar
  96. 96.
    Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85(5):1206–11.PubMedCentralPubMedGoogle Scholar
  97. 97.
    Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(1):85–90.PubMedGoogle Scholar
  98. 98.
    Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol. 2013;43(1):219–27.PubMedGoogle Scholar
  99. 99.
    Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol. 2013;15(2):198–207.PubMedCentralPubMedGoogle Scholar
  100. 100.
    Yang Y-P, Chang Y-L, Huang P-I, Chiou G-Y, Tseng L-M, Chiou S-H, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol. 2012;227(3):976–93.PubMedGoogle Scholar
  101. 101.
    Chang C-J, Chiang C-H, Song W-S, Tsai S-K, Woung L-C, Chang C-H, et al. Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nerv Syst. 2012;28(3):363–73.PubMedGoogle Scholar
  102. 102.
    Liu D, Hu G, Long G, Qiu H, Mei Q, Hu G. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012;33(5):682–90.PubMedCentralPubMedGoogle Scholar
  103. 103.
    Reed S, Li H, Li C, Lin J. Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun. 2011;407(3):450–5.PubMedGoogle Scholar
  104. 104.
    Yang M-Y, Lee H-T, Chen C-M, Shen C-C, Ma H-I. Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells. Int J Mol Sci. 2014;15(6):11013–29.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969–78.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Kostrouchová M, Kostrouch Z, Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha). 2007;53(2):37–49.Google Scholar
  107. 107.
    Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734–41.PubMedGoogle Scholar
  108. 108.
    Chen C-H, Chang Y-J, Ku MSB, Chung K-T, Yang J-T. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med (Berl). 2011;89(3):303–15.Google Scholar
  109. 109.
    Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MVM, Sminia P, Stalpers LJA. Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol. 2012; 107(1):61–7.PubMedGoogle Scholar
  110. 110.
    Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012;14(1):34–43.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Gil del Alcazar CR, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res. 2014;20(5):1235–48.PubMedGoogle Scholar
  112. 112.
    Wang W, Long L, Yang N, Zhang Q, Ji W, Zhao J, et al. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin. 2013;34(5):681–90.PubMedCentralPubMedGoogle Scholar
  113. 113.
    Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am. 2010;21(1):17–29.PubMedGoogle Scholar
  114. 114.
    Toda M. Glioma stem cells and immunotherapy for the treatment of malignant gliomas. ISRN Oncol. 2013;2013:673793.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 2005;11(23):8304–11.PubMedGoogle Scholar
  116. 116.
    Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J. 1997; 44(1):43–51.PubMedGoogle Scholar
  117. 117.
    Ueda R, Yoshida K, Kawakami Y, Kawase T, Toda M. Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol. 2004;21(1):35–8.PubMedGoogle Scholar
  118. 118.
    Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64(14):4980–6.PubMedGoogle Scholar
  119. 119.
    Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 1997;150(6):2143–52.PubMedCentralPubMedGoogle Scholar
  120. 120.
    Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247–54.PubMedGoogle Scholar
  121. 121.
    Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002;8(9):2851–5.PubMedGoogle Scholar
  122. 122.
    Hashiba T, Izumoto S, Kagawa N, Suzuki T, Hashimoto N, Maruno M, et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo). 2007;47(4):165–70. discussion 170.Google Scholar
  123. 123.
    Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother Hagerstown Md 1997. 2000;23(5):511–8.Google Scholar
  124. 124.
    Schmitz M, Wehner R, Stevanovic S, Kiessling A, Rieger MA, Temme A, et al. Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11. Cancer Lett. 2007;245(1–2):331–6.PubMedGoogle Scholar
  125. 125.
    Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37.PubMedGoogle Scholar
  126. 126.
    Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 1995;15(3):244–56.PubMedGoogle Scholar
  127. 127.
    Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1–14F (ab′)2—a preliminary report. J Neurooncol. 1995;24(1):109–22.PubMedGoogle Scholar
  128. 128.
    Riva P, Arista A, Franceschi G, Frattarelli M, Sturiale C, Riva N, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55(23 Suppl):5952s–6s.PubMedGoogle Scholar
  129. 129.
    Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Höök M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991;115(4):1127–36.PubMedGoogle Scholar
  130. 130.
    Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain J-F, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596–603.PubMedGoogle Scholar
  131. 131.
    Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104(10):4071–6.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474–85.PubMedCentralPubMedGoogle Scholar
  133. 133.
    Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67(12):5957–64.PubMedGoogle Scholar
  134. 134.
    Kahlon KS, Brown C, Cooper LJN, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160–6.PubMedGoogle Scholar
  135. 135.
    Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res. 2012;18(21):5949–60.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D’Apuzzo M, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012;18(8):2199–209.PubMedCentralPubMedGoogle Scholar
  137. 137.
    Stastny MJ, Brown CE, Ruel C, Jensen MC. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine + cytolytic T cells. J Pediatr Hematol Oncol. 2007;29(10):669–77.PubMedGoogle Scholar
  138. 138.
    Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol Med (Camb Mass). 2001;7(10):659–67.Google Scholar
  139. 139.
    Ji J, Black KL, Yu JS. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am. 2010;21(1):159–66.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842–7.PubMedGoogle Scholar
  141. 141.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973–9.PubMedGoogle Scholar
  142. 142.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515–25.PubMedGoogle Scholar
  143. 143.
    Grauer OM, Sutmuller RPM, van Maren W, Jacobs JFM, Bennink E, Toonen LWJ, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2008;122(8):1794–802.PubMedGoogle Scholar
  144. 144.
    Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol. 2009;11(5):529–42.PubMedCentralPubMedGoogle Scholar
  145. 145.
    Piccirillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444(7120):761–5.PubMedGoogle Scholar
  146. 146.
    Lim DA, Tramontin AD, Trevejo JM, Herrera DG, García-Verdugo JM, Alvarez-Buylla A. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron. 2000;28(3):713–26.PubMedGoogle Scholar
  147. 147.
    Panchision DM, McKay RDG. The control of neural stem cells by morphogenic signals. Curr Opin Genet Dev. 2002;12(4):478–87.PubMedGoogle Scholar
  148. 148.
    Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29(28):8884–96.PubMedGoogle Scholar
  149. 149.
    Venugopal C, Li N, Wang X, Manoranjan B, Hawkins C, Gunnarsson T, et al. Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells. Stem Cell Res. 2012;8(2):141–53.PubMedGoogle Scholar
  150. 150.
    Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507–11.PubMedCentralPubMedGoogle Scholar
  151. 151.
    Jung J-W, Park S-B, Lee S-J, Seo M-S, Trosko JE, Kang K-S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One. 2011;6(11):e28068.PubMedCentralPubMedGoogle Scholar
  152. 152.
    Song CW, Lee H, Dings RPM, Williams B, Powers J, Santos TD, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2:362.PubMedCentralPubMedGoogle Scholar
  153. 153.
    Wurth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability. Cell Cycle. 2013;12(1):145–56.PubMedCentralPubMedGoogle Scholar
  154. 154.
    Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer. 2011;129(11):2720–31.PubMedGoogle Scholar
  155. 155.
    Zhuang W, Long L, Zheng B, Ji W, Yang N, Zhang Q, et al. Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Cancer Sci. 2012;103(4):684–90.PubMedGoogle Scholar
  156. 156.
    Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, et al. Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 2012;31(22):2715–24.PubMedGoogle Scholar
  157. 157.
    Morelli MB, Nabissi M, Amantini C, Farfariello V, Ricci-Vitiani L, di Martino S, et al. The transient receptor potential vanilloid-2 cation channel impairs glioblastoma stem-like cell proliferation and promotes differentiation. Int J Cancer. 2012;131(7):E1067–77.PubMedGoogle Scholar
  158. 158.
    Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem. 2007;282(9):6854–62.PubMedGoogle Scholar
  159. 159.
    Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev. 2011;7(1):119–29.PubMedCentralPubMedGoogle Scholar
  160. 160.
    Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2–12.PubMedGoogle Scholar
  161. 161.
    Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 2005;12(3):284–94.PubMedGoogle Scholar
  162. 162.
    Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 2009;100(7):1154–64.PubMedCentralPubMedGoogle Scholar
  163. 163.
    Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68(15):6043–8.PubMedCentralPubMedGoogle Scholar
  164. 164.
    Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008;3(11):e3769.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Section of NeurosurgeryGeisel School of Medicine at DartmouthLebanonUSA
  2. 2.Department of Neurological SurgeryVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations